FDA Approves Colchicine for CV Prevention The FDA has approved colchicine for cardiovascular prevention in adults with established atherosclerotic disease or multiple risk factors, making it the first anti-inflammatory medicine with such an indication. https://t.co/MEqASrWWMb https://t.co/TmoLEvlPXI

• https://bit.ly/46lbJj7

Medicare and Commercial claims analysis shows 1 #RA pts at risk for H Zoster 2 RA + HZ = more Hospitalizations & ED visits, esp in 30d after HZ 3 Higher total costsalso higher in month after HZ https://t.co/iKmvYDqj87 https://t.co/BeZCmMJse7

• https://bit.ly/3plw47b

Indian study of 943 AIRD patients (43% RA) starting biologics or JAKi, had TB screening with IGRA assay. 125 pts were IGRA pos. and had LTBI; 124/125 received anti-TB prophylaxis. IGRA Accuracy in predicting absence of TB reactivation = 99.6% https://t.co/KI9vGWpS59 https://t.co/Ne33P51koD

• https://bit.ly/3Ps0ejH

What is Colchicine Worth? This week a new colchicine FDA approval, rising rate of IgG4 related disease and what's the safest biologic? https://t.co/VAeP4lPKL6 https://t.co/QUPRqxTz5z

• https://bit.ly/3Nr3CbY

Predictors of DAPSA28 remission in #PsA starting 1st TNF-inhibitor (13 369 bio-naive pts from 13 Euro registries) showed 6 mo remission 25% and 12 retention 63%. Remission predictors: younger age, Dz duration, males (OR 1.85), CRP >10 (OR 1.52) https://t.co/KNaFynAlXM https://t.co/okO0fLqM54

• https://bit.ly/3Xmn5iO

Abatacept Safety Outcomes Across 7 European Registries A multinational registry analysis of rheumatoid arthritis receiving abatacept has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy. https://t.co/hAj3UZjbHJ https://t.co/eQHjEgelRM

• https://bit.ly/3XqxQAo

2023 EULAR Recommendations on Imaging in Crystal-Induced Arthritis These included 5 overarching principles & 10 recommendations on the role of imaging in making a diagnosis, monitoring, predicting, guiding therapy, and patient education in CiA. https://t.co/tZW3vNCl7T https://t.co/8IB3q3xNY6

• https://bit.ly/3XlmKNf

Chronic Pain Management tools 1 Medication 2 Physical Therapy 3 Cognitive-Behavioral Therapy 4 Mindfulness Meditation 5 Acupuncture 6 Massage 7 Heat/Cold 8 TENS 9 Yoga/Tai Chi 10 Support groups https://t.co/hb6ACoS6Xn https://t.co/AZRM873J6Z

• https://bit.ly/42WgCfu

RheumNow’s newly launched Poster Hall features sponsor-generated clinical trial posters designed to educate and inform. Posters addressing vasculitis, AxSpa and nrAxSpa, and PMR now available. https://t.co/0U47rSH7KB https://t.co/SNy8Egw59z

• https://bit.ly/3JqvjRb

Dazodalibep: A Glimmer of Hope is Sjogren's Syndrome? https://t.co/5GNUZolPsz https://t.co/bIFKPjWBM0

• https://bit.ly/46cXi0B

Should JAKs be ‘Tyk’ed off? https://t.co/w1FpDeGCT1

• https://bit.ly/44bY6B0

Ultrasonography May Improve OA Pain Prediction Dr. Bella Mehta reports on POS0107 from EULAR 2023 in Milan, Italy. https://t.co/ZHBdWPWTys https://t.co/JLIScNVZGB

• https://bit.ly/3NkMlBd

EULAR 2023 Lupus Highlights https://t.co/CGybJRjDDK https://t.co/2kkB1hX2J5

• https://bit.ly/3NHODvA

Are bDMARDs, tsDMARDs and biosimilar DMARDs cost effective? The use of methotrextate with either bDMARDs, tsDMARDs or bsDMARDs was not shown to be cost effective, even though reduced disease activity and improved patient quality of life. Read more--https://t.co/4nBp0ML8Kl https://t.co/5YXCotHlYK

• https://bit.ly/3NIBdzu

Cancer Risk From RA, Not the Drugs A large US claims analysis shows RA patients were nearly 2 times more likely (than those without RA) to develop lymphoma or lung cancer and that commonly used RA treatments were also unlikely to increase cancer risk. https://t.co/6yrc0TsT53 https://t.co/WRQzeFoR1Z

• https://bit.ly/3JnS8F9